Overview of Gynazol

What Type of Antifungal Medication is Gynazol?

Gynazol is a prescription-only pharmaceutical product classified as a vaginal anti-infective and an antifungal agent. Its active substance is butoconazole nitrate, a synthetic imidazole derivative that belongs specifically to the azole antifungal class.

This categorization places the medication within a group of drugs utilized for their targeted action against pathogenic fungi, particularly Candida spp. The efficacy of this substance class is specialized for its role in treating yeast infections. Gynazol is designated as a regulated human prescription drug primarily intended for appropriate use in women who require focused antifungal treatment.

Composition and Formulation: The Butoconazole Nitrate Cream

Gynazol is formulated as a 2% vaginal cream and is designed exclusively for vaginal administration. It is a single active component product, typically supplied as a single-dose preparation, which provides a key differentiating factor from multi-day treatment regimens.

This specific cream dosage form is engineered to facilitate localized drug delivery. Butoconazole nitrate is contained within a specialized emulsion base that is designed to ensure the drug remains concentrated at the site of infection within the vaginal tissues. This formulation promotes focused antifungal agent activity while minimizing systemic exposure.

General Therapeutic Purpose of this Imidazole Derivative

The general purpose of this azole antifungal is the local management of fungal conditions by actively addressing the root cause, primarily vulvovaginal candidiasis caused by organisms like Candida albicans.

The therapeutic benefit is achieved through the butoconazole nitrate interfering with the structural integrity of the fungal cell. This mechanism involves disruption of essential sterol synthesis, leading to the growth inhibition and cellular damage of the pathogen. This targeted pharmacological action aims to resolve the fungal infection by neutralizing the causative organism at the affected site.

What side effects are possible with Gynazol?

Possible Side Effects and Safety Information

The safety profile for butoconazole nitrate 2% vaginal cream (Gynazol) is predominantly characterized by adverse reactions localized to the site of application, as documented in government regulatory labeling. The most frequently observed events are classified as common, occurring in 1% to 10% of patients in clinical trials.

Common Adverse Reactions

Adverse effects are primarily mapped to the Reproductive System and Breast Disorders system-organ-class, reflecting the topical administration. Common reactions include:

Vulvar/Vaginal Burning, Itching, Soreness, or Swelling
Abdominal Pain or Pelvic Cramping

Serious Safety Considerations

The official prescribing information notes the potential for serious adverse reactions, specifically hypersensitivity or allergic reactions, to the drug or any of its components. Symptoms may include rash, hives, swelling of the face, tongue, or throat, or severe dizziness.

Population-Specific Safety Statements

Regulatory documents include specific safety classifications for particular groups:

Population	Official Regulatory Statement
Pregnancy	Classified as Pregnancy Category C; use only if potential benefit justifies potential risk to the fetus.
Lactation	It is not known whether the drug is excreted in human milk; caution should be exercised when administered to a nursing woman.
Pediatric Use	The safety and effectiveness in children have not been established.

Safety Restrictions and Limitations

A critical constraint relates to the formulation's composition: the cream contains mineral oil, which can weaken latex or rubber products such as condoms or vaginal contraceptive diaphragms. Use of these barrier products is typically restricted for a period following treatment to avoid device compromise. Furthermore, a history of hypersensitivity to butoconazole nitrate or its components is a strict contraindication for use.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Gynazol

Official regulatory documents classify the risk of systemic overdose following the intended vaginal administration of Gynazol (Butoconazole Nitrate 2% Vaginal Cream) as unlikely to occur.

This assessment is based on the single-dose nature of the product and the low systemic absorption of butoconazole following its local application. Therefore, no specific systemic signs or symptoms are formally documented in regulatory labeling for overdose via the prescribed route.

The primary circumstance that triggers official emergency guidance is accidental oral ingestion of the vaginal cream. In this event, immediate medical help must be sought. Patients are specifically directed to contact a physician or local Poison Control center immediately for guidance.

Classification Element	Official Regulatory Statement
Antidote Status	No specific antidote is known for butoconazole overdose.
Management	Treatment consists of symptomatic and supportive therapy.

The official overdose structure is constrained by the absence of a specific reversal agent, focusing the required procedural steps on general supportive care for the patient.

Therapeutic Uses of Gynazol

Gynazol (butoconazole nitrate) is commonly used for the local management of Vulvovaginal Candidiasis (VVC), an infection associated with the overgrowth of Candida species, most frequently Candida albicans.

The primary therapeutic domain for Gynazol is applied across areas where additional symptomatic support is needed, supporting the management of symptoms associated with the infection. It is relevant in conditions characterized by periods of heightened symptoms and is used for managing symptoms that interfere with daily functioning, particularly those associated with acute symptomatic episodes of VVC. Its use is relevant for addressing symptoms related to inflammatory or irritative states, such as itching (pruritus), burning, and associated soreness.

“This therapy is commonly used to help manage the acute episode and contribute to easing disruptive symptomatic discomfort.”

Support for Symptoms Related to Vulvovaginal Discomfort

Gynazol is applied across domains where short-term symptom management is appropriate to address symptom clusters that include symptoms related to physical discomfort. This targeted symptomatic relief contributes to improved comfort and helps ease the overall symptom load during the symptomatic phases.

Regulatory References

National Institutes of Health (NIH) DailyMed

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Gynazol

Official regulatory documents define specific populations who can or cannot use Gynazol (butoconazole nitrate vaginal cream, 2%).

Populations for Whom Use is Contraindicated

Classification	Population/Condition
Absolute Prohibition	Patients with a known history of hypersensitivity (allergy) to butoconazole nitrate or any other component of the cream.

Populations with Conditional or Restricted Eligibility

Classification	Population/Condition	Restriction Basis
Conditional Use	Pregnant Women (FDA Category C)	Safety and effectiveness have not been established. Use is only justified if the potential benefit outweighs the risk to the fetus, requiring physician supervision.
Use Not Established	Children (under 12 years old)	Safety and effectiveness have not been established in this age group.
Caution Advised	Nursing Mothers	It is unknown if the drug is excreted in human milk; caution is advised when administering to a nursing woman.

Eligibility-Related Restrictions

Concurrent Product Use: The cream contains mineral oil, which may weaken latex or rubber products such as condoms or diaphragms. Therefore, use of these products is not recommended within 72 hours following treatment.
Underlying Conditions: Recurrent or persistent infections may be a sign of a serious underlying medical condition, such as HIV, necessitating a full re-evaluation of the diagnosis before use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction profile for butoconazole nitrate vaginal cream, focusing strictly on regulatory findings.

Interaction Scope and Classification

Due to the minimal systemic absorption of the active ingredient, butoconazole nitrate, clinically significant systemic drug-drug interactions are not anticipated. Official regulatory labeling documents confirm that there are no known interactions with other systemically administered medicinal products, food, or alcohol. Similarly, metabolic interactions involving Cytochrome P450 enzymes or transporter-mediated interactions are not documented.

Formulation-Based Product Incompatibility and Timing Requirements

The primary documented interaction is a physical incompatibility related to the cream's formulation, not the active substance's pharmacology.

Interacting Product Category	Officially Documented Restriction
Latex or Rubber Barrier Contraceptives	Use is restricted for 72 hours after treatment.

An excipient, mineral oil, is documented in the prescribing information to potentially compromise the structural integrity of products made from latex or rubber, such as condoms and vaginal contraceptive diaphragms. This incompatibility necessitates a strict timing-based restriction. The use of these barrier contraceptives must be avoided for a period of at least 72 hours (three full days) following administration to prevent a documented risk of reduced contraceptive efficacy. This timing rule is the sole mandatory procedural constraint documented in the interaction profile.

Mechanism of Action

The core action of Gynazol (butoconazole) is to act as an inhibitor of the essential fungal enzyme lanosterol 14-alpha demethylase (L-14DM). This enzyme is targeted because it is critical in the biosynthesis pathway responsible for creating ergosterol, the primary structural component of the fungal cell membrane.

By blocking the conversion step necessary for ergosterol production, the mechanism causes the rapid depletion of this lipid in the membrane, leading to its structural compromise and an increase in its permeability. This failure in the membrane's integrity is the crucial physiological consequence, resulting in the uncontrolled leakage of the fungal cell's internal contents. This mechanism exhibits selective toxicity, as the target enzyme is unique to the fungal organism.

The culmination of this mechanistic cascade is the death of the fungal organism through overwhelming metabolic and structural damage, producing a fungicidal effect.

Dosage and Administration Information

Administration Guidelines for Gynazol

Gynazol (butoconazole nitrate 2% vaginal cream) is administered as a single-dose regimen. Its usage focuses on the specific method and quantity of delivery as outlined for the product.

Dosing and Administration Protocol

Instruction Entity	Detail
Route of administration	Intravaginal administration is the designated method.
Dosing schedule	One full applicatorful (approximately 5 grams of 2% cream, delivering approx 100 mg butoconazole nitrate).
Timing Principle	Administration is typically carried out once, at bedtime.
Preparation requirements	Use the prefilled, disposable applicator supplied with the product. Do not remove the applicator tip or warm the applicator prior to use.
Course Duration	The standard regimen is a single-course of therapy.

Procedural Constraints and Special Populations

For proper use, the product involves the administration of the cream via the specific pre-measured applicator supplied with the prescription. If clinical symptoms persist following this one-time administration, repeat diagnostic testing is indicated to re-evaluate the condition before considering subsequent treatment.

Two key procedural constraints are identified. First, tampons should not be used during the treatment period as they may absorb the medication. Second, the cream contains mineral oil, which can impact the integrity of certain latex or rubber products; therefore, the use of such barrier products is not recommended for 72 hours after the cream has been administered. The safety and efficacy for the single-dose product have not been established in patients under 18 years of age.

Recent Clinical Evidence

Research Evidence and Overview of Studies for Gynazol

This section provides a factual overview of the clinical research and study designs used in the development and evaluation of butoconazole nitrate 2% vaginal cream (Gynazol), based exclusively on official regulatory documents and peer-reviewed scientific literature. This information contributes to the broader evidence landscape but is not intended to provide clinical advice or individual treatment recommendations.

Evidence for Vulvovaginal Candidiasis (VVC)

The core research studying butoconazole nitrate was studied for Vulvovaginal Candidiasis (VVC), which is commonly known as a vaginal yeast infection. The evidence base available includes short-term Randomized Controlled Trials (RCTs). These studies were structured to evaluate butoconazole nitrate against an inactive cream (a vehicle control).

Research was studied for outcomes related to physical discomfort and physiological changes. Specifically, studies were conducted during periods of increased symptom activity and focused on two main measures: Clinical Cure Rate (looking at symptom resolution, such as reduced itching and burning) and Mycological Eradication Rate (laboratory findings showing the absence of Candida fungus).

Comparison of Butoconazole Nitrate to Other Treatments

Research has explored butoconazole nitrate in RCTs where it was evaluated against other established treatments for VVC, including other azole antifungal medications. Studies monitored outcomes related to physical discomfort and laboratory findings when butoconazole nitrate was evaluated against different treatment regimens.

Studies in Specific Patient Populations and Limitations

Butoconazole nitrate was primarily studied and evaluated in non-pregnant adult women who had symptomatic VVC. The results apply only to the populations studied, and the evidence base contributes to understanding symptom patterns in this group. A key research limitation is that the safety and measured outcomes for pregnant women have not been fully established, as this group was generally excluded from the core efficacy trials.

Additionally, while studies report how symptoms evolved in the observed populations during the short-term follow-up, there is limited information for long-term outcomes beyond the short-term follow-up. The primary research was studied for infections caused by Candida albicans, and data for outcomes related to other, less common non-albicans Candida species remains limited.

Key Studies & References National Institutes of Health (NIH) DailyMed: GYN-A-ZOL 1-day (butoconazole nitrate) cream

Frequently Asked Questions (FAQ)

Common questions about Gynazol (FAQ)

Q: Is Gynazol the same kind of medication as Monistat?

A: Gynazol, which contains butoconazole, and Monistat, which contains miconazole, both belong to the same pharmacological class, known as azole antifungals. These medications work in a similar way by targeting the fungal cell membrane to treat infections like vulvovaginal candidiasis. Official studies have evaluated Gynazol against other azole antifungals.

Q: Can Gynazol cause a burning sensation right after application?

A: According to official product information, vulvar/vaginal burning, itching, soreness, or swelling are among the common adverse reactions reported in clinical trials. If irritation is severe, or symptoms worsen, contact a healthcare provider for advice and guidance.

Q: Can I use Gynazol if I am close to starting my menstrual period?

A: Official guidance emphasizes that tampons should not be used during the treatment period as they can absorb the medicine and interfere with the drug's effectiveness. While official instructions do not strictly prohibit use during menstruation, absorption may be a concern. It is important to follow the provided administration instructions. If you have concerns about timing, consult your healthcare provider.

Q: Is it normal to see some discharge or leakage after using the Gynazol cream?

A: Yes, because Gynazol is a cream designed for intravaginal application, some leakage or discharge is common and generally expected. The medication is usually administered at bedtime to allow it to remain localized. The official guidance advises against using tampons to manage discharge, as tampons may absorb the medicine.

Q: How long does the effect of Gynazol last after the single application?

A: Gynazol is specifically formulated as a single-dose, extended-release vaginal cream. Official information indicates that the formulation is designed to remain localized and gradually release the medication over a period of up to several days at the site of infection. This mechanism supports the single-course treatment regimen.

Q: What happens if I accidentally miss a day, even though it's a single dose (e.g., if it leaks out)?

A: Gynazol is a standardized single-dose treatment that must be administered as one full applicatorful. Official product information indicates that if clinical symptoms persist or worsen following the one-time administration, repeat diagnostic testing is required to re-evaluate the condition before considering further treatment.

Q: Is it possible to have an allergic reaction to Gynazol?

A: Yes, serious adverse reactions, specifically hypersensitivity or allergic reactions to the drug or any of its components, are possible. A known history of hypersensitivity is a strict contraindication for use. If you experience symptoms such as rash, hives, swelling of the face, tongue, or throat, seek emergency medical assistance immediately.

Q: Can Gynazol be used for recurrent yeast infections?

A: Regulatory warnings indicate that recurrent or persistent infections may be a sign of a more serious underlying medical condition. In these cases, it is necessary to have a full re-evaluation of the diagnosis by a healthcare provider before use.

Q: Is there an age limit for who can use Gynazol?

A: According to official prescribing information, the safety and effectiveness in children have not been established. The single-dose product is not established for use in patients under 18 years of age.

Q: How long after using Gynazol is it safe to have sexual intercourse?

A: The cream contains mineral oil, which may weaken latex or rubber products such as condoms and diaphragms. Because of this incompatibility, the use of these barrier contraceptives is not recommended for 72 hours after treatment. For guidance on non-barrier intercourse, consult a healthcare provider.

Q: What does 'imidazole' mean in the context of how Gynazol works?

A: Gynazol's active ingredient, butoconazole, is chemically classified as a synthetic imidazole derivative, which is a type of azole antifungal compound. This chemical group is known for interfering with the fungal cell membrane's structure, and this mechanism is intended to produce a fungicidal effect against the causative organisms.

Q: Are there any contraindications for Gynazol besides pregnancy and allergies?

A: The only absolute prohibition is a known history of hypersensitivity (allergy) to the drug or any of its components. Use is conditional and requires caution in certain populations, including pregnant women (FDA Category C), nursing mothers, and children, due to unestablished safety and effectiveness in these groups.

Q: Is there a generic version of Gynazol available?

A: Yes, butoconazole nitrate vaginal cream, 2% is available in generic formulations. These generic versions are reviewed by regulatory agencies and are considered therapeutically equivalent to the original brand name product.

Q: What are the signs that Gynazol is not working for the infection?

A: If your clinical symptoms persist or worsen after you have used the single dose of Gynazol, this may indicate the medication was not fully effective. If this happens, official guidance requires further diagnostic testing to re-evaluate the condition.

Q: Does Gynazol interact with supplements like probiotics or herbal remedies?

A: Due to the minimal amount of drug absorbed into the body, clinically significant systemic drug-drug interactions are not anticipated with other systemically administered medicinal products. However, interactions with specific over-the-counter supplements or herbal remedies are not directly documented in the official product information.

Q: What should I do if the Gynazol cream accidentally gets into my eyes?

A: Gynazol is formulated strictly for intravaginal use only. Topical products of this type are generally advised not to be used near the eyes. In such a case, immediate rinsing of the eyes with water is often recommended.

How should Gynazol be stored and disposed of?

Official Storage and Disposal Instructions

All storage, handling, and disposal requirements for Gynazol (butoconazole nitrate) are defined by official government regulatory agencies.

Requirement	Official Regulatory Statement
Storage Temperature	Store at Controlled Room Temperature of 25 C (77 F). Permitted excursions are 15 C to 30 C.
Avoid	Do not freeze and avoid heat above 30 C (86 F).
Protection	Keep the medication in the original container, and keep the container tightly closed and out of the reach of children.
Handling Precaution	The mineral oil in the cream may weaken latex or rubber products (like condoms/diaphragms). Use of these products is not recommended for 72 hours after treatment.
Disposal	Throw away unused or expired medicine and the single-use applicator according to official safe drug disposal guidelines.

Gynazol